Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Invest. 2012 Dec;30(10):712-20. doi: 10.3109/07357907.2012.727934. Epub 2012 Oct 8.

Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports.

Author information

  • 1Departments of Medical Oncology and Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Abstract

Ipilimumab 3 mg/kg was the first agent to improve survival of pretreated advanced melanoma patients. Nonconventional response patterns to ipilimumab have been reported widely, but most of these data were from studies with ipilimumab 10 mg/kg. Here, case reports from five patients treated within an expanded access program (EAP) with ipilimumab at its licensed dose of 3 mg/kg illustrate the efficacy of ipilimumab in an expanded access setting and the range of different tumor response patterns encountered. The durable clinical benefit seen in these patients despite the observed atypical response patterns highlights the necessity for comprehensive clinical decision making.

PMID:
23043499
[PubMed - indexed for MEDLINE]
PMCID:
PMC3536036
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare Icon for PubMed Central
    Loading ...
    Write to the Help Desk